Reduction of Insulin Related Preventable Severe Hypoglycemic Events in Hospitalized Children

Amy Poppy1, Claudia Retamal-Munoz2, Melanie Cree-Green3

  • 1Quality and Patient Safety, Children's Hospital Colorado, Aurora, Colorado; amy.poppy@childrenscolorado.org.

Pediatrics
|June 19, 2016
PubMed

Insights

Implementing multiple interventions significantly reduced preventable hypoglycemia events in pediatric patients receiving insulin. This multi-faceted approach improved inpatient diabetes care safety.

Area of Science:

  • Pediatric Endocrinology
  • Hospital Patient Safety
  • Diabetes Management

Background:

  • Insulin is a high-risk medication frequently used in hospitals.
  • Improper insulin administration can cause hypoglycemia, a major complication in hospitalized patients with diabetes.
  • Preventing hypoglycemia is crucial for improving inpatient diabetes care.

Purpose of the Study:

  • To reduce preventable insulin-related hypoglycemia events in a tertiary care pediatric hospital.
  • To enhance the safety of insulin administration for hospitalized children.

Main Methods:

  • Instituted nursing and physician education programs.
  • Implemented electronic medical record order sets and communication templates.
  • Developed and enforced new care guidelines for insulin use.

Main Results:

  • Reduced preventable hypoglycemia events from 1.4 to 0.4 per 100 insulin days.
  • Demonstrated a significant decrease in insulin-related adverse events.

Conclusions:

  • A multidisciplinary approach, including an insulin safety committee, effectively decreased severe preventable hypoglycemia.
  • Sustained improvements in safety for pediatric patients on insulin were achieved.
Abstract

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.2K
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.1K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
897
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
957
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.8K
SBAR II: Application of SBAR01:14

SBAR II: Application of SBAR

SBAR is an effective communication tool used by healthcare professionals to communicate patient information accurately. SBAR stands for Situation, Background, Assessment, and Recommendation. For a better understanding, an example is given below.
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
6.7K